Kopp Family Office’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Kopp Family Office’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-136,895	Closed	-$15.6M	–	23
2022 Q4	$15.6M	Sell	136,895 -405,648	-75%	-$33.7M	9.38%	4
2022 Q3	$33.6M	Sell	542,543 -1,500	-0.3%	-$105K	27.33%	1
2022 Q2	$43.4M	Sell	544,043 -792	-0.1%	-$75K	30.48%	1
2022 Q1	$57.3M	Sell	544,835 -3,880	-0.7%	-$378K	30.98%	1
2021 Q4	$59.1M	Buy	548,715 +7,820	+1%	+$853K	25.86%	1
2021 Q3	$59.3M	Sell	540,895 -5,880	-1%	-$610K	23.52%	2
2021 Q2	$51.2M	Hold	546,775	–	–	21.19%	2
2021 Q1	$50.3M	Buy	546,775 +109,800	+25%	+$9.27M	22.36%	2
2020 Q4	$32M	Buy	436,975 +9,510	+2%	+$707K	13.02%	3
2020 Q3	$33.2M	Buy	427,465 +111,140	+35%	+$7.65M	18.04%	2
2020 Q2	$17.6M	Buy	+316,325	New	+$13.5M	9.5%	2

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Kopp Family Office's HZNP Position: Q1 2023 in Review

Kopp Family Office sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 136,895 shares — an estimated $15.6M sold.

Kopp Family Office first reported a position in HZNP in Q2 2020 and held it in 11 quarters. The position peaked at $59.3M in Q3 2021. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

Kopp Family Office reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Kopp Family Office sold 136,895 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $15.6M.
Kopp Family Office first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2020 and held it in 11 quarters.
Kopp Family Office's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $59.3M in Q3 2021.
553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Kopp Family Office's 13F filing for Q1 2023, filed 15 May 2023.